TARA: Protara Therapeutics, Inc. Stock

by  •  • Comments Off on TARA: Protara Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 128.94
Enterprise Value ($M) 77.18
Book Value ($M) 81.79
Book Value / Share 3.96
Price / Book 1.58
NCAV ($M) 72.78
NCAV / Share 3.53
Price / NCAV 1.77

Profitability (mra)
Return on Invested Capital (ROIC) -0.49
Return on Assets (ROA) -0.48
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 9.85
Current Ratio 9.85

Balance Sheet (mrq) ($M)
Current Assets 85.08
Assets 94.09
Liabilities 12.30
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-18 13G Opaleye Management Inc. 8.15 -32.98
11-14 13G/A CVI Investments, Inc. 2.80 0.00
11-14 13G Woodline Partners LP 7.40
04-25 13G Ra Capital Management, L.p. 9.99 23.46
04-22 13G Citadel Advisors Llc 5.70
02-14 13G/A Orbimed Advisors Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-12-13 244,539 715,529 34.18
2024-12-12 155,375 547,010 28.40
2024-12-11 155,040 884,943 17.52
2024-12-10 554,565 3,241,528 17.11
2024-12-09 543,160 1,932,944 28.10

(click for more detail)

Similar Companies
SPRY – ARS Pharmaceuticals, Inc. STRO – Sutro Biopharma, Inc.
SUPN – Supernus Pharmaceuticals, Inc. TBPH – Theravance Biopharma, Inc.
TCRX – TScan Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io